Neuroendocrine / sexual health
Melanotan II
Mechanism not verified by source image · Peptide
Evidence at a glance
Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.
Open in the interactive library →Compare with other compounds →
Records (1)
H
Human clinical / research
Human clinical / research
Melanotan II pilot phase I study
Administration reported for this specific study or labeled indication.
Context: Three healthy male volunteers
Human study regimen: Amount: 0.01 mg/kg starting dose; Route: Subcutaneous; Frequency: Alternating treatment days; Species: Human; Population: Three healthy male volunteers
Limitations: Single-blind exploratory tanning study. The starting dose is the observed study parameter.
Route: Subcutaneous
Open this exact record in the library →Suggest a correction
CONTINUE THE RESEARCH
Follow the pathway.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →
Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.